How does PODD's Q1 2025 earnings forecast compare?

Insulet Corporation (PODD) is forecasted to report earnings per share (EPS) of approximately $0.81 for Q1 2025, compared to the previous quarter's EPS of $1.15. This indicates a decline in earnings, which could be due to increased expenses, such as a 22.6% rise in selling, general & administrative expenses and a 44.3% rise in research and development costs. The estimated revenue for Q1 2025 is $542.81 million, reflecting a 17-21% increase in Omnipod revenue growth forecast. However, this is overshadowed by a projected 45%-55% decline in Drug Delivery revenue for 2025. Insulet's competitors, such as Tandem Diabetes Care (TNDM), are also expected to report negative EPS of approximately -$0.6 for the same period, with an estimated revenue of $220.16 million. It's important to note that these forecasts are based on current market conditions and may be subject to change. |code|Ticker|Name|Date|Estimate EPS|market_code| |---|---|---|---|---|---| |TNDM|TNDM.O|Tandem Diabetes Care|2024 Q2|-0.54|185| |PODD|PODD.O|Insulet|2024 Q2|0.56|185| |TNDM|TNDM.O|Tandem Diabetes Care|2024 Q3|-0.41|185| |PODD|PODD.O|Insulet|2024 Q3|0.78|185| |TNDM|TNDM.O|Tandem Diabetes Care|2024 Q4|-0.21|185| |PODD|PODD.O|Insulet|2024 Q4|1.03|185| |TNDM|TNDM.O|Tandem Diabetes Care|2025 Q1|-0.6|185| |PODD|PODD.O|Insulet|2025 Q1|0.81|185| |code|Ticker|Name|Date|Estimate Revenue|market_code| |---|---|---|---|---|---| |TNDM|TNDM.O|Tandem Diabetes Care|2024 Q2|2.0563E8|185| |PODD|PODD.O|Insulet|2024 Q2|4.604E8|185| |TNDM|TNDM.O|Tandem Diabetes Care|2024 Q3|2.2366E8|185| |PODD|PODD.O|Insulet|2024 Q3|5.1876E8|185| |TNDM|TNDM.O|Tandem Diabetes Care|2024 Q4|2.513E8|185| |PODD|PODD.O|Insulet|2024 Q4|5.827E8|185| |TNDM|TNDM.O|Tandem Diabetes Care|2025 Q1|2.2016E8|185| |PODD|PODD.O|Insulet|2025 Q1|5.4281E8|185|